Radium and targeted alpha therapy in prostate cancer: new data and concepts von Sartor, O.

Volltext

Patient-reported quality-of-life analysis of radium-223 dichloride from the phase III ALSYMPCA study von Nilsson, S., Cislo, P., Sartor, O., Vogelzang, N.J., Coleman, R.E., O'Sullivan, J.M., Reuning-Scherer, J., Shan, M., Zhan, L., Parker, C.

Volltext

An exploratory analysis of alkaline phosphatase, lactate dehydrogenase, and prostate-specific antigen dynamics in the phase 3 ALSYMPCA trial with radium-223 von Sartor, O., Coleman, R.E., Nilsson, S., Heinrich, D., Helle, S.I., O’Sullivan, J.M., Vogelzang, N.J., Bruland, Ø., Kobina, S., Wilhelm, S., Xu, L., Shan, M., Kattan, M.W., Parker, C.

Volltext

Impact of cabazitaxel on 2-year survival and palliation of tumour-related pain in men with metastatic castration-resistant prostate cancer treated in the TROPIC trial von Bahl, A., Oudard, S., Tombal, B., Özgüroĝlu, M., Hansen, S., Kocak, I., Gravis, G., Devin, J., Shen, L., de Bono, J.S., Sartor, A.O.

Volltext

Alpha Emitter Radium-223 and Survival in Metastatic Prostate Cancer von Parker, C, Nilsson, S, Heinrich, D, Helle, S.I, O'Sullivan, J.M, Fosså, S.D, Chodacki, A, Wiechno, P, Logue, J, Seke, M, Widmark, A, Johannessen, D.C, Hoskin, P, Bottomley, D, James, N.D, Solberg, A, Syndikus, I, Kliment, J, Wedel, S, Boehmer, S, Dall'Oglio, M, Franzén, L, Coleman, R, Vogelzang, N.J, O'Bryan-Tear, C.G, Staudacher, K, Garcia-Vargas, J, Shan, M, Bruland, Ø.S, Sartor, O

Volltext

Baseline neutrophil–lymphocyte ratio (NLR) is associated with survival and response to treatment with second-line chemotherapy for advanced prostate cancer independent of baseline... von Lorente, D., Mateo, J., Templeton, A.J., Zafeiriou, Z., Bianchini, D., Ferraldeschi, R., Bahl, A., Shen, L., Su, Z., Sartor, O., de Bono, J.S.

Volltext

Next generation radiotheranostics promoting precision medicine von Pomykala, K.L., Hadaschik, B.A., Sartor, O., Gillessen, S., Sweeney, C.J., Maughan, T., Hofman, M.S., Herrmann, K.

Volltext

Advances in targeted alpha therapy for prostate cancer von De Vincentis, G., Gerritsen, W., Gschwend, J.E., Hacker, M., Lewington, V., O’Sullivan, J.M., Oya, M., Pacilio, M., Parker, C., Shore, N., Sartor, O.

Volltext

Validation of metastasis-free survival as a surrogate endpoint for overall survival in localized prostate cancer in the era of docetaxel for castration-resistant prostate cancer von Xie, W., Ravi, P., Buyse, M., Halabi, S., Kantoff, P., Sartor, O., Soule, H., Clarke, N., Dignam, J., James, N., Fizazi, K., Gillessen, S., Mottet, N., Murphy, L., Parulekar, W., Sandler, H., Tombal, B., Williams, S., Sweeney, C.J.

Volltext

History of Sage-Grouse (Centrocercus spp.) In New Mexico von Braun, Clait E, Williams III, Sartor O

Volltext

Re-treatment with radium-223: first experience from an international, open-label, phase I/II study in patients with castration-resistant prostate cancer and bone metastases von Sartor, O., Heinrich, D., Mariados, N., Méndez Vidal, M.J., Keizman, D., Thellenberg Karlsson, C., Peer, A., Procopio, G., Frank, S.J., Pulkkanen, K., Rosenbaum, E., Severi, S., Trigo Perez, J.M., Wagner, V., Li, R., Nordquist, L.T.

Volltext

Comparative analysis on the expression of L1 loci using various RNA-Seq preparations von Kaul, Tiffany, Morales, Maria E., Sartor, Alton O., Belancio, Victoria P., Deininger, Prescott

Volltext

Alpha Particle Radiobiology for Radium-223 (“Alpharadin”): The Fortuitous “Goldilocks” Effect Observed for Hormone-resistant Metastatic Prostate Cancer von Macklis, R.M, Sartor, O

Volltext

Statin use and outcome in metastatic castration-resistant prostate cancer (mCRPC) patients (pts) treated in the TROPIC trial von Lorente, D., De Velasco Oria, G.A., Carles, J., Gillessen, S., Fizazi, K., Joshua, A., Eisenberger, M., Sartor, O., de Bono, J.S.

Volltext

Association of grade ≥3 neutropenia (NP) with outcomes in patients with metastatic castration-resistant prostate cancer (mCRPC) receiving cabazitaxel von Meisel, A., de Wit, R., Oudard, S., Sartor, O., Stenner-Liewen, F., Shun, Z., Ozatilgan, A., Eisenberger, M., de Bono, J.S.

Volltext

Clinical outcome with radium-223 (Ra-223) in patients (pts) previously treated with abiraterone (Abi) or enzalutamide (Enza): A retrospective study of real-world (RW) data from pts... von Higano, C.S., Tombal, B., Miller, K., Saad, F., Sartor, O., Tangirala, K., Jiao, X., Kalinovsky, J., Sternberg, C.N.

Volltext

Post hoc responder analysis of health‐related quality of life (HRQL) in patients with metastatic castration‐resistant prostate cancer (mCRPC) receiving cabazitaxel in the phase III... von Thiery Vuillemin, A., Fizazi, K., Sartor, O., Oudard, S., Bury, D., Guillonneau, S., Ozatilgan, A., Eisenberger, M., de Bono, J.S.

Volltext

Androgen Deprivation Therapy Impact on Quality of Life and Cardiovascular Health, Monitoring Therapeutic Replacement von Trost, Landon W., Serefoglu, Ege, Gokce, Ahmet, Linder, Brian J., Sartor, Alton O., Hellstrom, Wayne J.G.

Volltext

High PSA anxiety and low health literacy skills: drivers of early use of salvage ADT among men with biochemically recurrent prostate cancer after radiotherapy? von Mahal, B.A., Chen, M.-H., Bennett, C.L., Kattan, M.W., Sartor, O., Stein, K., D'Amico, A.V., Nguyen, P.L.

Volltext

External Beam Radiation Therapy (EBRT) Use and Safety With Radium-223 Dichloride (Ra-223) in Patients With Castration-Resistant Prostate Cancer (CRPC) and Symptomatic Bone Metastas... von Finkelstein, S.E, Michalski, J.M, O'Sullivan, J, Parker, C, Garcia-Vargas, J, Sartor, O

Volltext